Nevro Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Nevro şirketinin toplam hissedar öz sermayesi $273.6M ve toplam borcu $222.3M olup, bu da borç-öz sermaye oranını 81.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $595.6M ve $322.0M dir.

Anahtar bilgiler

81.2%

Borç/özkaynak oranı

US$222.27m

Borç

Faiz karşılama oranı	n/a
Nakit	US$277.04m
Eşitlik	US$273.64m
Toplam yükümlülükler	US$322.01m
Toplam varlıklar	US$595.65m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 1N7 'nin kısa vadeli varlıkları ( $479.2M ) kısa vadeli yükümlülüklerini ( $95.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: 1N7 şirketinin kısa vadeli varlıkları ( $479.2M ) uzun vadeli yükümlülüklerini ( $226.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 1N7 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 1N7 şirketinin borç/öz sermaye oranı son 5 yılda 79.9% seviyesinden 81.2% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 1N7 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 1N7, serbest nakit akışı her yıl % 9.5 oranında tarihi oranda azalmaya devam ederse 3 yıldan fazla bir süre yeterli nakit akışına sahip olur

Nevro Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Nevro Corp. Announces the Publication of New Data in Medical Devices

Third quarter 2024 earnings released: US$0.41 loss per share (vs US$0.65 loss in 3Q 2023)

Nevro Corp. Reaffirms Earnings Guidance for the Year 2024

Nevro Corp. Announces New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy

Nevro Corp. to Report Q3, 2024 Results on Nov 11, 2024

Second quarter 2024 earnings released: US$0.53 loss per share (vs US$0.69 loss in 2Q 2023)

Nevro Revises Earnings Guidance for the Full Year 2024

Nevro Corp. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$0.70 loss per share (vs US$0.98 loss in 1Q 2023)

Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024

Nevro Corp. to Report Q1, 2024 Results on May 07, 2024

New minor risk - Shareholder dilution

Nevro Corp., Annual General Meeting, May 23, 2024

Full year 2023 earnings released: US$2.56 loss per share (vs US$0.085 profit in FY 2022)

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Nevro Corp. to Report Q4, 2023 Results on Feb 21, 2024

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Nevro Corp. Increases Revenue Guidance for the Full-Year 2023

Nevro Corp. Provides Revenue Guidance for the Fourth Quarter of 2023

Third quarter 2023 earnings released: US$0.65 loss per share (vs US$2.30 profit in 3Q 2022)

New major risk - Revenue and earnings growth

Nevro Corp. to Report Q3, 2023 Results on Nov 01, 2023

Nevro Corp. Announces New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Nevro Announces Launch of HFX Connect in Europe and CE Marking of Expanded Labelling for the HFX SCS system

Nevro Corp. Revises Earnings Guidance for the Full-Year 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$0.71 loss in 2Q 2022)

Independent Director recently bought €160k worth of stock

Nevro Corp. Announces Executive Changes

Nevro Corp. to Report Q2, 2023 Results on Aug 01, 2023

First quarter 2023 earnings released: US$0.98 loss per share (vs US$0.98 loss in 1Q 2022)

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2023

Full year 2022 earnings released: EPS: US$0.085 (vs US$3.77 loss in FY 2021)

Nevro Corp. to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society 26th Annual Meeting

Nevro Corp. to Report Q4, 2022 Results on Feb 16, 2023

Third quarter 2022 earnings released: EPS: US$2.30 (vs US$1.44 loss in 3Q 2021)

Nevro Corp. Updates Earnings Guidance for the Year Ending December 31, 2022

Nevro Corp. Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain

Nevro Corp. to Report Q3, 2022 Results on Nov 02, 2022

Nevro Corp. Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropathy

Nevro Corp. Announces Executive Changes

Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy

Second quarter 2022 earnings released: US$0.71 loss per share (vs US$0.62 loss in 2Q 2021)

Nevro Corp. Revises Earnings Guidance for the Full Year 2022

Nevro and Boston Scientific Corporation Announce the Settlement of Their Ongoing Intellectual Property Litigations

Nevro Corp. to Report Q2, 2022 Results on Aug 03, 2022

Nevro Corp. Announces the Complete 12-Month Results from the SENZA-PDN Randomized Controlled Trial

General Counsel recently bought €95k worth of stock

First quarter 2022 earnings released: US$0.98 loss per share (vs US$0.85 loss in 1Q 2021)

Nevro Corp. Provides Earnings Guidance for the Second Quarter of 2022; Reiterates Earnings Guidance for the Year 2022

Nevro Corp., Annual General Meeting, May 26, 2022

Nevro Corp. to Report Q1, 2022 Results on May 04, 2022

Chairman of the Board recently bought €187k worth of stock

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Nevro Announces Publication of Twelve Month Data from SENZA-NSRBP Randomized Controlled Trial in Journal of Neurosurgery: Spine

Nevro Announces FDA Approval for Expanded Labeling for its 10 kHz High Frequency Spinal Cord Stimulation System for Treatment of Non-Surgical Refractory Back Pain (NSRBP)

Nevro Corp. Announces Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant and Durable Benefits of Nevro's 10 kHz Therapy

Nevro Corp. Announces Unitedhealthcare Coverage for High-Frequency 10 KHZ Therapy for the Treatment of Painful Diabetic Neuropathy

Independent Director recently bought €178k worth of stock

Nevro Corp. Announces Settlement of IP Litigation with Nalu Medical

Nevro Corp. Announces Three Important Clinical Data Publications for Treating Painful Diabetic Neuropathy with 10 kHz Therapy

General Counsel recently bought €176k worth of stock

Third quarter 2021 earnings released: US$1.44 loss per share (vs US$0.29 loss in 3Q 2020)

High number of new directors

Nevro Corp. Withdraws Full Year 2021 Guidance

Second quarter 2021 earnings released: US$0.62 loss per share (vs US$1.21 loss in 2Q 2020)

Nevro Corp. Provides Preliminary, Unaudited Revenue Guidance for the Second Quarter of 2021

Nevro Corp. SENZA-PDN Clinical Data Presentation at the American Diabetes Association 81st Scientific Sessions

Nevro Corp. Provides Earnings Guidance for the Second Quarter Ended June 30, 2021 and Full Year 2021

First quarter 2021 earnings released: US$0.85 loss per share (vs US$0.78 loss in 1Q 2020)

Nevro Corp. Provides Earnings Guidance for the Second Quarter Ended June 30, 2021

Nevro Introduces HFX, New Comprehensive Brand Identity Combining Nevro's Innovative Technologies, Advanced Therapies and End-To-End Patient Support

New 90-day low: €130

Full year 2020 earnings released: US$2.47 loss per share (vs US$3.37 loss in FY 2019)